KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Finished Goods (2016 - 2025)

Sarepta Therapeutics has reported Finished Goods over the past 10 years, most recently at $65.3 million for Q4 2025.

  • Quarterly results put Finished Goods at $65.3 million for Q4 2025, up 38.36% from a year ago — trailing twelve months through Dec 2025 was $65.3 million (up 38.36% YoY), and the annual figure for FY2025 was $65.3 million, up 38.36%.
  • Finished Goods for Q4 2025 was $65.3 million at Sarepta Therapeutics, up from $64.8 million in the prior quarter.
  • Over the last five years, Finished Goods for SRPT hit a ceiling of $78.0 million in Q3 2024 and a floor of $26.7 million in Q4 2021.
  • Median Finished Goods over the past 5 years was $47.2 million (2023), compared with a mean of $47.4 million.
  • Biggest five-year swings in Finished Goods: skyrocketed 713.44% in 2021 and later fell 23.62% in 2024.
  • Sarepta Therapeutics' Finished Goods stood at $26.7 million in 2021, then surged by 42.78% to $38.1 million in 2022, then soared by 62.02% to $61.8 million in 2023, then fell by 23.62% to $47.2 million in 2024, then skyrocketed by 38.36% to $65.3 million in 2025.
  • The last three reported values for Finished Goods were $65.3 million (Q4 2025), $64.8 million (Q3 2025), and $71.0 million (Q2 2025) per Business Quant data.